Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJain, N.en
dc.contributor.authorIto, S.en
dc.contributor.authorTian, X.en
dc.contributor.authorKurlander, R.en
dc.contributor.authorBattiwalla, M.en
dc.contributor.authorLu, K.en
dc.contributor.authorSavani, B.en
dc.contributor.authorMalkovska, V.en
dc.contributor.authorRezvani, K.en
dc.contributor.authorLe, R.en
dc.contributor.authorShenoy, A.en
dc.contributor.authorHourigan, C.en
dc.contributor.authorKeyvanfar, K.en
dc.contributor.authorKoklanaris, E.en
dc.contributor.authorSuperata, J.en
dc.contributor.authorMuranski, P.en
dc.contributor.authorBarrett, A.en
dc.contributor.authorYong, A.en
dc.identifier.citationBone Marrow Transplantation, 2014; 50(2):189-196en
dc.description.abstractAlthough there are now fewer allo-SCTs performed for CML, leukemic relapse post transplant remains a persistent problem. To better define clinical and biological parameters determining postrelapse outcome, we studied 59 patients with CML relapsing after HLA-identical sibling allo-SCT between 1993 and 2008. Eighteen (30.5%) were transplanted in advanced phase and 41 (69.5%) in chronic phase. With a median follow-up from relapse of 7.9 years, 5-year post relapse survival (PRS) was 62%. Multivariate analysis found disease status at transplant, time to diagnosis of relapse from transplant and pretransplant tyrosine kinase inhibitor (TKI) use as significant factors associated with PRS. Analysis of BCR-ABL transcript expression in the hematopoietic progenitor compartment was performed in 36 patients (22 relapsed, 8 non-relapsed and 6 TKI alone controls). Patients with BCR-ABL expression in their early hematopoietic stem cell compartment (Lineage−CD34+CD38−CD90+) had worse survival irrespective of the disease status. We conclude that disease status remains the strongest clinical prognostic factor for PRS in CML following allo-SCT. The persistence of BCR-ABL expression in the progenitor cell compartment in some patients after SCT emphasizes the need to target CML-leukemia stem cells.en
dc.description.statementofresponsibilityNA Jain, S Ito, X Tian, R Kurlander, M Battiwalla, K Lu, BN Savani, V Malkovska, K Rezvani, RQ Le, A Shenoy, CS Hourigan, K Keyvanfar, E Koklanaris, J Superata, P Muranski, AJ Barrett, and ASM Yongen
dc.publisherNature Publishing Groupen
dc.rights© 2015 Macmillan Publishers Limited All rights reserveden
dc.subjectHumans; Recurrence; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Survival Rate; Retrospective Studies; Follow-Up Studies; Adult; Middle Aged; Female; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Allograftsen
dc.titleClinical and biological predictors of outcome following relapse of CML post-allo-SCTen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidYong, A. [0000-0001-9452-1533]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.